530:
Development and validation of the parent-reported drug hypersensitivity quality of life questionnaire
Sunday, March 4, 2018
South Hall A2 (Convention Center)
Nisarat Chantaravisarut, MD, Thatchai Wirodwanich, MD, Wipa Jessadapakorn, MD, Pasuree Sangsupawanich, MD, PhD, Tippawan Liabsuetrakul, MD, PhD, Araya Yuenyongviwat, MD
RATIONALE: Drug hypersensitivity in children impact on quality of life over the patients and their caregivers. Measurement quality of life in children is different from adult because the children can’t answer the question by themselves. The research aims to developed and validated the Parent-reported Drug Hypersensitivity Quality of Life Questionnaire (P-DrHy-Q)

METHODS: At first, the 21-item scale was generated by researchers. Then, the scale was asked for opinion from 3 expert opinion. After adjusted in contents and language the scale was answered by caregivers (N=97). Then, factor analysis was carried out selecting the items from the final scale and Croncach’s alpha assessed internal consistency. Finally the test-retest reliability was done in another group of caregivers (N=10).

RESULTS: The 21-item scale could grouping to 6 factors. However, the inappropriated in some factor, therefore, the reducing factor and item was done by statistical analysis. The final 12-item scale included two factors: mental health and social activity. The scale had a good internal consistency (Cronbach’s α = 0.897) and the test-retest associations were good (R= 0.9439; P < 0.001)

CONCLUSIONS: P-DrHy-Q is the first scale for assessment of the interaction of biopsychosocial factors on drug allergy that includes the dyad carer-child. It show good internal consistency and reliability. Its application might be relevant for future research, and it can provide the clinician and the researcher with a solid tool to define which type of psychosocial support is required to provide a more comprehensive care in drug hypersensitivity.